Mounjaro is a GLP-1 receptor agonist intended for use when lifestyle measures such as diet and exercise alone do not adequately control blood glucose levels. The Mounjaro 12.5 mg KwikPen is a prefilled, multi-dose pen designed for ease of self-administration at home. Each pen contains four fixed doses of the specified strength: for example, a 12.5 mg pen holds a total of 50 mg of tirzepatide (4 doses × 12.5 mg), 0.6 ml each. Patients inject one dose per week, so each pen is designed to last for one month.

Many patients often ask how many doses are in Mounjaro 12.5 mg KwikPen, and some also wonder whether it’s safe to take a different dose from a Mounjaro 12.5 mg KwikPen. It’s important to follow the prescribed dosage exactly and not adjust doses manually, as the pen delivers fixed, pre-measured doses to ensure safe and effective blood-sugar control.

This GLP-1 medication is specifically indicated for type 2 diabetes and should not be used for type 1 diabetes or diabetic ketoacidosis. Patients with a history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) must avoid this treatment. Always use Mounjaro under the supervision of a qualified healthcare provider.

Mounjaro 12.5mg Kwik Pen is approved for:

• Improves blood sugar control in adults with type 2 diabetes mellitus through the action of a GLP-1 receptor agonist.

• Used in combination with diet and exercise for better glycaemic management.

• This GLP-1 medication may be used alone or together with other diabetes medicines, as prescribed by a healthcare provider.

Tirzepatide in this pen works as a GLP-1 receptor agonist, mimicking the action of two natural hormones in your body. These hormones help lower blood sugar in three key ways: by helping your body release insulin when needed, reducing how much sugar your liver produces, and slowing down how quickly food leaves your stomach. This GLP-1 mechanism helps you feel full for longer, reduces how much you eat, and keeps your blood sugar steady throughout the day.

Like most diabetes medications, this injection can interact with certain other drugs and affect how well it works or increase the risk of side effects. Inform your doctor about all the medicines you take, especially:

• Insulin or sulfonylureas: When taken together, the risk of hypoglycemia increases. Dose adjustments may be needed.

• Oral contraceptives: Tirzepatide may reduce the effectiveness of birth control pills due to delayed gastric emptying. Alternative or additional contraceptive methods are advised.

• Warfarin: May affect INR levels. Close monitoring is essential if you are on blood thinners.

• Diuretics or antihypertensives: Sudden drops in blood pressure may occur, especially if dehydration happens due to nausea or vomiting.

• Thyroid medications: Use caution in patients with a history of thyroid issues, particularly medullary thyroid carcinoma.

Always carry a list of your medications to share with your doctor or pharmacist to prevent serious interactions.

Unused KwikPens

• Keep unused KwikPens in the fridge at 2°C to 8°C — not in the freezer.

• They’re good to use till the expiry date if kept refrigerated.

• Never freeze the pen. If it gets frozen, throw it away in a sharps disposal container.

• Store in original carton to protect from light.

After You Start Using a KwikPen

• You can keep it at room temperature (up to 30°C) for up to 30 days.

• Store away from direct heat and sunlight.

• Throw it away 30 days after first use, even if there’s some medicine left.

• Also discard after you’ve taken all 4 weekly doses, in a sharps disposal container.

Inject once weekly into your abdomen, thigh, or upper arm, with or without food, at any time of the day. Always try to use it on the same day each week.
Remember:

• Each pen has four doses of its stated strength (12.5mg pen = total 50mg in pen).

• One dose per week means one pen is a one-month supply.

• Never share your pen.

• Rotate injection sites to avoid skin thickening.

Common Side Effects:

• Nausea

• Vomiting

• Diarrhea

• Constipation

• Decreased appetite

• Injection site reactions (redness, itching)

Serious Side Effects:

• Pancreatitis (severe abdominal pain)

• Gallbladder issues (pain in the upper right abdomen)

• Allergic reactions (rash, swelling, difficulty breathing)

• Kidney problems due to dehydration from vomiting or diarrhea

• Thyroid tumors (rare but serious; watch for neck swelling or hoarseness).

• Inject in a different spot each time to avoid skin thickening.

• Avoid skipping doses; set reminders for your weekly injection.

• Stay hydrated, especially if experiencing vomiting or diarrhea.

• Eat balanced meals and monitor your blood sugar regularly.

• Do not use the pen if it has been frozen or left out for too long.

1. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management

2. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjarotm-tirzepatide-injection-first-and

3. https://www.lilly.com/en-CA/resources/faq/mounjaro-kwikpen/strengths-and-doses

4. https://pi.lilly.com/ca/mounjaro-ca-ifu-kp.pdf